Efficiency of complex therapy in patients with a- and hypogammaglobulinemia
https://doi.org/10.21886/2219-8075-2018-9-4-57-62
Abstract
Objective: assessment of the effectiveness of the use of Polymuramil in complex with IVG therapy with patients with CVID and ХLA with insufcient replacement therapy.
Materials and methods: there were 10 patients with insufcient effectiveness of IVIG replacement therapy, receiving complex IVIG therapy and immunomodulator Polymuramil at a dose of 200 μg / 0.5 ml No. 5 intramuscularly every other day, under study. Surface and intracellular markers of cells of the congenital and acquired immune response, serum immunoglobulins of class A, M, G - in the radial immunodiffusion in the Mancini gel, the oxygen-dependent metabolic activity of neutrophils in NST-test were assessed with the help of flow cytometry, before and afer 3 months and a comparative analysis of the obtained data was conducted.
Results: analysis of the data revealed a signifcant increase in markers of lymphocyte activation, which indicates the induction properties of the studied immunomodulator by increasing the activation potentials of the cellular link of adaptive immunity in patients with primary immunodefciency.
Summary: in patients with a genetically mediated defect of the humoral immunity against the background of complex therapy with the use of Polymuramil, the activation of congenital and adaptive immunity is registered, which is confrmed, in addition to laboratory indexes, by a decrease in the frequency of exacerbations of chronic inflammatory diseases.
About the Authors
D. I. Krolevets
Rostov State Medical University, Rostov-on-Don
Russian Federation
Darya I. Krolevec, graduate student of department of clinical immunology and allergology
Russian Federation
Darya I. Krolevec, graduate student of department of clinical immunology and allergology
L. P. Sizyakina
Rostov State Medical University, Rostov-on-Don
Russian Federation
Lyudmila P. Sizyakina, PhD, prof., head of department of
clinical immunology and allergology
Russian Federation
Lyudmila P. Sizyakina, PhD, prof., head of department of
clinical immunology and allergology
I. I. Andreeva
Rostov State Medical University, Rostov-on-Don
Russian Federation
Irina I. Andreeva, PhD, associate professor of department of clinical immunology and allergology
Russian Federation
Irina I. Andreeva, PhD, associate professor of department of clinical immunology and allergology
A. A. Yakovlev
Rostov State Medical University, Rostov-on-Don
Aleksej A. Yakovlev, PhD, prof., head of department of
gastroenterology and endoscopy with the course of clinical
pharmacology
Aleksej A. Yakovlev, PhD, prof., head of department of
gastroenterology and endoscopy with the course of clinical
pharmacology
O. A. Bashtovaya
Rostov State Medical University, Rostov-on-Don
Olga A. Bashtovaya, graduate student of department of
gastroenterology and endoscopy with the course of clinical
pharmacology
Olga A. Bashtovaya, graduate student of department of
gastroenterology and endoscopy with the course of clinical
pharmacology
References
1. Khaitov RM. Allergology and immunology: national guidelines: a short edition. Moscow: GEOTAR-Media; 2012. (In Russ)
2. Sizyakina LP, Andreeva II. Compensatory reactions of the immune system with a defect in the synthesis of antibodies - agammaglobulinemia // Rossiyskiy allergologicheskiy zhurnal. 2016;2:14-18. (In Russ)
3. Bousfha A, Jeddane L, Picard C et al. Te 2017 IUIS Phenotypic Classifcation for Primary Immunodefciencies. Journal of Clinical Immunology. 2018;38(1):129–143. DOI:10.1007/s10875-017-0465-8
4. Abbott JK, Gelfand EW. Common variable immunodefciency: diagnosis, management, and treatment. Immunology and Allergy Clinics. 2015;35(4):637-658. DOI: 10.1016/j.iac.2015.07.009
5. Latysheva EA, Latysheva TV, Martynova IA. Evaluation of the effectiveness and safety of IVIG «IG VENA» in patients with a primary violation of antibody synthesis // Rossiyskiy allergologicheskiy zhurnal. 2016;1:16-22. (In Russ)
6. Khaitov RM, Ilyina NI. Clinical immunology and allergology. Federal clinical guidelines. Moscow: Farmus Print Media; 2015. (In Russ)
7. Sizyakina LP, Andreeva II. Primary agammaglobulinemia as a model cooperative relationships humoral and cell mediated immunity // Immunologiya. 2016;1:14-16 (In Russ) DOI:10.18821/0206-4952-2016-37-1-14-16
8. Paschenkov MV, Alkhazova BI, Lvov VL, Pinegin BV. Te use of inhibitory analysis to study the mechanisms of action of the muramylpeptide immunomodulator “Polymuramil”// Meditsiniskaya immunologiya. 2013;1:21-28. (In Russ)
9.
Review
For citations:
Krolevets D.I., Sizyakina L.P., Andreeva I.I., Yakovlev A.A., Bashtovaya O.A. Efficiency of complex therapy in patients with a- and hypogammaglobulinemia. Medical Herald of the South of Russia. 2018;9(4):57-62. (In Russ.) https://doi.org/10.21886/2219-8075-2018-9-4-57-62
Views:
558
Email this article 